Baylor College of Medicine

Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19) (H-47759)

Description

Content

In this study, we are enrolling patients who present to our Emergency Department with mild-moderate COVID-19. The goal is to evaluate the efficacy and safety of Dapagliflozin in those patients. This is a phase III, international, randomized, double-blind, placebo-controlled study.

Learn more information.

IRB: H-47759

Status:

Active

Created:

Back to topback-to-top